These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 34219)

  • 1. [Cases of abnormal movements].
    Singer B
    Sem Hop; 1979 Jan 8-15; 55(1-2):83-4. PubMed ID: 34219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Present-day treatment of dyskinesias (author's transl)].
    Fonsegrive J
    Sem Hop; 1979 Jan 8-15; 55(1-2):88-9. PubMed ID: 34220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].
    Lhermitte F; Agid Y; Feuerstein C; Serre F; Signoret JL; Studler JM; Bonnet AM
    Rev Neurol (Paris); 1977; 133(8-9):445-54. PubMed ID: 929037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Trazodone in involuntary pathologic movements].
    Rubino R; Provera P; Gilardengo P; Penza MT
    Riv Neurol; 1984; 54(1):52-73. PubMed ID: 6718959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutical approach to involuntary movements (author's transl)].
    Allain H; Sabouraud O
    Sem Hop; 1979 Feb 8-15; 55(5-6):262-4. PubMed ID: 219537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Abnormal movements and shaking in geriatrics (author's transl)].
    Chabaud R; Guenoun M; Taddei JP; Guillou J
    Sem Hop; 1979 Mar 8-15; 55(9-10):465-9. PubMed ID: 38513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
    Pourcher E; Bonnet AM; Kefalos J; Dubois B; Agid Y
    Mov Disord; 1989; 4(3):195-201. PubMed ID: 2779590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable remission of tardive dyskinesia by L-dopa.
    Ludatscher JI
    J Clin Psychopharmacol; 1989 Feb; 9(1):39-41. PubMed ID: 2565346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
    Baron MS; Dalton WB
    Mov Disord; 2003 Oct; 18(10):1208-9. PubMed ID: 14534933
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Lhermitte F; Agid Y; Signoret JL; Studler JM
    Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of tardive and L-dopa-induced dyskinesias to antidepressants.
    el-Awar M; Freedman M; Seeman P; Goldenberg L; Little J; Solomon P
    Can J Neurol Sci; 1987 Nov; 14(4):629-31. PubMed ID: 3690436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Ferger B
    Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormal movements induced by L-dopa. New therapeutic possibilities].
    Eisenring J-J ; Constantinidis J; Dick P; Yanniotis G; Tissot R
    Schweiz Med Wochenschr; 1975 Jan; 105(4):121-4. PubMed ID: 1124379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.